212 related articles for article (PubMed ID: 34384466)
1. XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor.
Pan L; Cheng C; Duan P; Chen K; Wu Y; Wu Z
J Exp Clin Cancer Res; 2021 Aug; 40(1):255. PubMed ID: 34384466
[TBL] [Abstract][Full Text] [Related]
2. Verdinexor, a Selective Inhibitor of Nuclear Exportin 1, Inhibits the Proliferation and Migration of Esophageal Cancer via XPO1/c-Myc/FOSL1 Axis.
Ou L; Wang X; Cheng S; Zhang M; Cui R; Hu C; Liu S; Tang Q; Peng Y; Chai R; Xie S; Wang S; Huang W; Wang X
Int J Biol Sci; 2022; 18(1):276-291. PubMed ID: 34975332
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway.
Zhao C; Yang ZY; Zhang J; Li O; Liu SL; Cai C; Shu YJ; Pan LJ; Gong W; Dong P
J Transl Med; 2022 Sep; 20(1):434. PubMed ID: 36180918
[TBL] [Abstract][Full Text] [Related]
4. Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication
Jorquera PA; Mathew C; Pickens J; Williams C; Luczo JM; Tamir S; Ghildyal R; Tripp RA
J Virol; 2019 Feb; 93(4):. PubMed ID: 30541831
[TBL] [Abstract][Full Text] [Related]
5. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
[TBL] [Abstract][Full Text] [Related]
6. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
[TBL] [Abstract][Full Text] [Related]
7. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract][Full Text] [Related]
8. Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.
Pickens JA; Tripp RA
Viruses; 2018 Jan; 10(1):. PubMed ID: 29361733
[TBL] [Abstract][Full Text] [Related]
9. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.
Conforti F; Zhang X; Rao G; De Pas T; Yonemori Y; Rodriguez JA; McCutcheon JN; Rahhal R; Alberobello AT; Wang Y; Zhang YW; Guha U; Giaccone G
Cancer Res; 2017 Oct; 77(20):5614-5627. PubMed ID: 28819023
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
[TBL] [Abstract][Full Text] [Related]
12. Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.
Breit MN; Kisseberth WC; Bear MD; Landesman Y; Kashyap T; McCauley D; Kauffman MG; Shacham S; London CA
BMC Vet Res; 2014 Jul; 10():160. PubMed ID: 25022346
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.
Schmidt J; Braggio E; Kortuem KM; Egan JB; Zhu YX; Xin CS; Tiedemann RE; Palmer SE; Garbitt VM; McCauley D; Kauffman M; Shacham S; Chesi M; Bergsagel PL; Stewart AK
Leukemia; 2013 Dec; 27(12):2357-65. PubMed ID: 23752175
[TBL] [Abstract][Full Text] [Related]
14. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH
PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627
[TBL] [Abstract][Full Text] [Related]
15. In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals.
Widman DG; Gornisiewicz S; Shacham S; Tamir S
PLoS One; 2018; 13(10):e0200043. PubMed ID: 30332435
[TBL] [Abstract][Full Text] [Related]
16. Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.
Perwitasari O; Johnson S; Yan X; Howerth E; Shacham S; Landesman Y; Baloglu E; McCauley D; Tamir S; Tompkins SM; Tripp RA
J Virol; 2014 Sep; 88(17):10228-43. PubMed ID: 24965445
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
18. The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines.
Breitbach JT; Louke DS; Tobin SJ; Watts MR; Davies AE; Fenger JM
Vet Comp Oncol; 2021 Jun; 19(2):362-373. PubMed ID: 33438820
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of XPO1 impairs cholangiocarcinoma cell proliferation by triggering p53 intranuclear accumulation.
Zhao C; Ma B; Yang ZY; Li O; Liu SL; Pan LJ; Gong W; Dong P; Shu YJ
Cancer Med; 2023 Mar; 12(5):5751-5763. PubMed ID: 36200270
[TBL] [Abstract][Full Text] [Related]
20. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
